PRESS RELEASE: 31 October 2022, 17:40 CET
Biocartis Announces Nine Idylla™ Studies to be Published at Upcoming AMP 2022 Annual Meeting
Mechelen, Belgium, 31 October 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an revolutionary molecular diagnostics firm (Euronext Brussels: BCART), at this time pronounces the publication of 9 efficiency examine abstracts of its absolutely automated molecular diagnostics Idylla™ platform1 and assays2 on the annual assembly of the ‘Association for Molecular Pathology’ (AMP), a number one molecular diagnostics convention, going down between 1-5 November in Phoenix, Arizona (US). The research have been carried out by quite a lot of US laboratories and analysis institutes.
Among the research printed, 4 research on the Idylla™ GeneFusion Assay2 highlighted the strengths of Idylla™ testing together with excessive accuracy, ease-of-use and fast time-to-results. Furthermore, one examine carried out with the brand new SeptiCyte RAPID® EDTA3 blood suitable cartridges4 (CE-IVD, not 510(okay) cleared) on the Idylla™ platform, developed in collaboration with Immunexpress, concluded that the addition of the broadly used EDTA blood tube as a validated pattern kind has the potential to significantly improve the scientific utility of this new near-patient sepsis diagnostic.
Herman Verrelst, Chief Executive Officer of Biocartis, commented: “These studies are great, especially the data published on the Idylla™ GeneFusion Assay which shows the benefit of Idylla™ biomarker testing versus testing on more complex and hence slower technologies such as Next Generation Sequencing, often used very early on in the biomarker testing process. With Idylla™, the time-to-result of diagnostic testing is decreased, demonstrating the suitability of Idylla™ testing for rapid broad molecular profiling.”
The different research associated to the usage of the Idylla™ EGFR Assay, the Idylla™ MSI Assay and the Idylla™ NRAS-BRAF Assay2. The Idylla™ examine abstracts chosen for AMP 2022 could be downloaded right here.
During the AMP annual assembly, on 2 November 2022, Biocartis will host a free company workshop led by Dr. Rick Ledding, Histology Supervisor at Benefis Health Systems, sharing his expertise on the implementation of the Idylla™ platform in his laboratory: “Bringing Rapid Molecular Testing In House: How to Set Up a No-Hassle Workflow.”
— END —
More info:
Renate Degrave
Head of Corporate Communications & Investor Relations Biocartis
e-mail [email protected]
tel +32 15 631 729
cellular +32 471 53 60 64
About Biocartis
With its revolutionary and proprietary Idylla™ platform, Biocartis (Euronext Brussels: BCART) aspires to allow personalised drugs for sufferers all over the world by common entry to molecular testing, by making molecular testing actionable, handy, quick and appropriate for any lab. The Idylla™ platform is a completely automated sample-to-result, real-time PCR (Polymerase Chain Reaction) primarily based system designed to supply in-house entry to correct molecular info in a minimal period of time for sooner, knowledgeable therapy selections. Idylla™’s constantly increasing menu of molecular diagnostic assessments tackle key unmet scientific wants, with a spotlight in oncology. This is the quickest rising section of the molecular diagnostics market worldwide. Today, Biocartis affords assessments supporting melanoma, colorectal, lung and liver most cancers, in addition to for COVID-19, Flu, RSV and sepsis. For extra info, go to www.biocartis.com or comply with Biocartis on Twitter @Biocartis_ , Facebook or LinkedIn.
Biocartis and Idylla™ are registered logos in Europe, the United States and different international locations. The Biocartis and Idylla™ trademark and brand are used logos owned by Biocartis. Please check with the product labeling for relevant supposed makes use of for every particular person Biocartis product.
This press release shouldn’t be for distribution, instantly or not directly, in any jurisdiction the place to take action could be illegal. Any individuals studying this press release ought to inform themselves of and observe any such restrictions. Biocartis takes no accountability for any violation of any such restrictions by any particular person. This press release doesn’t represent a suggestion or invitation for the sale or buy of securities in any jurisdiction. No securities of Biocartis could also be provided or offered within the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration underneath the U.S. Securities Act of 1933, as amended.
Forward-looking statements
Certain statements, beliefs and opinions on this press release are forward-looking, which mirror the Company’s or, as applicable, the Company administrators’ or managements’ present expectations and projections regarding future occasions such because the Company’s outcomes of operations, monetary situation, liquidity, efficiency, prospects, progress, methods and the trade through which the Company operates. By their nature, forward-looking statements contain plenty of dangers, uncertainties, assumptions and different components that might trigger precise outcomes or occasions to vary materially from these expressed or implied by the forward-looking statements. These dangers, uncertainties, assumptions and components might adversely have an effect on the end result and monetary results of the plans and occasions described herein. A mess of things together with, however not restricted to, adjustments in demand, competitors and expertise, could cause precise occasions, efficiency or outcomes to vary considerably from any anticipated improvement. Forward-looking statements contained on this press release concerning previous tendencies or actions should not ensures of future efficiency and shouldn’t be taken as a illustration that such tendencies or actions will proceed sooner or later. In addition, even when precise outcomes or developments are in line with the forward-looking statements contained on this press release, these outcomes or developments might not be indicative of outcomes or developments in future durations. No representations and warranties are made as to the accuracy or equity of such forward-looking statements. As a end result, the Company expressly disclaims any obligation or endeavor to release any updates or revisions to any forward-looking statements on this press release because of any change in expectations or any change in occasions, situations, assumptions or circumstances on which these forward-looking statements are primarily based, besides if particularly required to take action by legislation or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such particular person’s officers or staff ensures that the assumptions underlying such forward-looking statements are free from errors nor does both settle for any accountability for the longer term accuracy of the forward-looking statements contained on this press release or the precise prevalence of the forecasted developments. You shouldn’t place undue reliance on forward-looking statements, which communicate solely as of the date of this press release.
1 The Idylla™ platform is cleared within the US underneath K163628. Idylla™ EGFR, BRAF, KRAS, MSI, NRAS-BRAF, ctEGFR, ctBRAF, ctKRAS, ctNRAS-BRAF and GeneFusion assays are all for Research Use Only within the United States, not to be used in diagnostic procedures. For extra info, go to https://www.biocartis.com/en-US
2 Except for the examine carried out on the brand new SeptiCyte RAPID® EDTA blood suitable cartridges (CE-IVD, not 510(okay) cleared), all research have been carried out with Idylla™ RUO assays, for analysis use solely, not to be used in diagnostic procedures
3 EDTA represents Ethylenediaminetetraacetic acid, which is the anticoagulant used for many hematology procedures (like figuring out and counting blood cells, blood typing, and many others.). Source: ksmedical.com, final consulted on 28 Oct 2022
4 In addition to blood samples collected in PAXgene blood RNA tubes (per the producer’s directions), this check is now additionally in a position to course of undiluted EDTA blood samples that are generally used for many hematology procedures, with outcomes out there in about one hour
